ArticleFrontiers in oncology2024
Clinical analysis of molecular typing of 146 cases of endometrial carcinoma.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolutionary perspectives on endometrial cancer: antagonistic pleiotropy.Molecular & cellular oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the application of TCGA molecular typing in endometrial carcinoma, compare the relationship between molecular typing and clinicopathologic features, and provide a new idea for individual treatment of patients. Methods: A total of 146 EC patients who underwent surgical treatment and TCGA molecular typing in Beijing Hospital from December 2019 to March 2023 were collected. The clinicopathologic features, immunohistochemistry, and prognosis of the four TCGA molecular types were analyzed retrospectively. Result: Among the 146 patients with endometrial cancer (EC), 8 patients (5.5%) exhibited the POLE hypermutant type, 29 patients (19.9%) displayed the MSI-H type, 94 patients (64.4%) presented the low copy-number type, and 15 patients (10.3%) manifested the high copy-number type. A comparative analysis of the four TCGA types and age yielded statistically significant results (p = 0.012). Notably, significant associations were observed between menopausal status, the expression of ER, PR, and the four TCGA types. However, no significant difference was observed in CA125 levels before surgery among the four TCGA types (p = 0.587). There were significant differences observed among the four TCGA types and pathological types, pathological grades, FIGO stage, lymph node metastasis, and LVSI. The progression-free survival (PFS) rates of patients with POLE hypermutation, MSI-H type, CNL type, and CNH type were 100%, 100%, 93.62%, and 73.3%, respectively. There was a statistically significant difference between the four groups(p=0.006). POLE mutant and MSI-H type patients have higher PFS, while high copy type patients have the lowest. Conclusions: TCGA molecular typing has feasibility and application value in the clinical application of endometrial cancer, and has a certain predictive effect on the prognosis of EC patients. It has a certain guiding significance for the individual treatment of patients with endometrial cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.